NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 5, 2008, Pages 1053-1056

  Livermore, David M ^a   Mushtaq, Shazad ^a   Warner, Marina ^a   Miossec, Christine ^b   Woodford, Neil ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Novexel SA   (France)

Author keywords

lactamase inhibitors; ESBLs; KPC carbapenemase; Metallo lactamases

Indexed keywords

BACTERIAL ENZYME; BETA LACTAMASE AMPC; BETA LACTAMASE CTX M; BETA LACTAMASE INHIBITOR; CARBAPENEMASE; CEFOTAXIME; CEFTAZIDIME; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; METALLO BETA LACTAMASE; NXL 104; PIPERACILLIN PLUS TAZOBACTAM; PORIN; PROTEIN KPC; PROTEIN OXA 48; PROTEIN SME; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG POTENTIATION; ENTEROBACTER AEROGENES; ENTEROBACTERIACEAE; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CEFOTAXIME; CEFTAZIDIME; ENTEROBACTERIACEAE; ENZYME INHIBITORS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE;

EID: 54549112247     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn320     Document Type: Article

References (11)

1. Robbins M, Cassettari M, Dencer C et al. In vitro activity of NXL 104(NXL), a new β-lactamase inhibitor, in combination with cefpodoxime (CPD) and cefixime (CFM) against 3rd generation cephalosporin-resistant isolates of species of the Enterobacteriaceae. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract F-1161, p. 187. American Society for Microbiology, Washington, DC, USA.
2. Livermore DM, Hawkey PM. CTX-M: Changing the face of ESBLs in the UK. J Antimicrob Chemother 2005; 56: 451-4.
3. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: Changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-74.
4. Lewis JS, Herrera M, Wickes B et al. First report of the emergence of CTX-M-type extended-spectrum β-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother 2007; 51: 4015-21.
5. Naas T, Bogaerts P, Bauraing C et al. Emergence of PER and VEB extended-spectrum β-lactamases in Acinetobacter baumannii in Belgium. J Antimicrob Chemother 2006; 58: 178-82.
6. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-51.
7. Woodford N, Dallow JW, Hill RL et al. Ertapenem resistance among Klebsielle and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents 2007; 29: 456-9.
8. Woodford N, Tiemo PM, Young K et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother 2004; 48: 4793-9.
9. Bradford PA, Bratu S, Urban C et al. Emergence of carbapenem-resistant Klebsialla species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin Infect Dis 2004; 39: 55-60.
10. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Sixth Edition: Approved Standard M7-A6. NCCLS, Villanova, PA, USA, 2003.
11. Merdjan H, Tarral AM, Gerard PLP et al. Safety, single dose pharmacokinetics, and pharmacodynamics of β-lactamase inhibitor NXL 104 in healthy young male adults. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract A-809, p. 26. American Society for Microbiology, Washington, DC, USA.